journal
MENU ▼
Read by QxMD icon Read
search

Clinical Neuropharmacology

journal
https://www.readbyqxmd.com/read/28195839/carbamazepine-toxicity-induced-spindle-coma-a-novel-case-report
#1
Bhumir Chauhan, Amitkumar Patanvadiya, Gopal Krishna Dash
A 9-year-old girl presented with alleged history of deliberate ingestion of 4 g of carbamazepine, following which she became comatose. A bedside electroencephalogram (EEG) was performed to rule out nonconvulsive status epilepticus, which showed presence of spindle coma (SC), not reactive to noxious stimuli. Following hemodialysis, a second EEG showed absence of SC and complete clinical recovery. We present this unique case of carbamazepine-induced SC, thereby highlighting the extent of the etiologic spectrum of SC and discussing the literature related to this association...
February 13, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28195838/the-use-of-zonisamide-for-the-treatment-of-psychiatric-disorders-a-systematic-review
#2
Massimiliano Buoli, Silvia Grassi, Valentina Ciappolino, Marta Serati, Alfredo C Altamura
OBJECTIVE: Traditional pharmacotherapy has undoubtedly improved the outcome of patients with psychiatric disorders, but partial efficacy or poor tolerability persists in a number of these subjects. Among different compounds, zonisamide has been used to address unmet needs of standard pharmacotherapy. The purpose of the present article is to provide a review about the use of zonisamide for the treatment of psychiatric conditions. METHODS: A research in the main database sources has been conducted to obtain an overview of the use of zonisamide in psychiatric disorders or associated conditions (obesity and smoking cessation)...
February 13, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28195837/the-effect-of-atomoxetin-use-in-the-treatment-of-attention-deficit-hyperactivity-disorder-on-the-symptoms-of-restless-legs-syndrome-a-case-report
#3
Saliha Baykal, Melih Nuri Karakurt
Attention-deficit/hyperactivity disorder (ADHD) is frequently accompanied with sleep disorders such as obstructive sleep apnea, periodic limb movement disorder, restless legs syndrome (RLS), and circadian rhythm disorder. We have limited information about the effects of medical therapies used in the treatment of ADHD on RLS. This article discusses the effects of atomoxetine treatment on both disorders in a patient followed by diagnoses of ADHD and RLS.
February 13, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28118168/increased-trichotillomania-symptoms-in-a-child-with-fluoxetine-treatment
#4
Çiğdem Yektaş, Ali Evren Tufan
Trichotillomania (TTM) is a mental disorder characterized by uncontrolled and impulsive hair pulling leading to hair loss, distress, and disordered functioning. Treatment choices include behavioral therapy (especially habit reversal training) and selective serotonin reuptake inhibitors. However, randomized controlled trials conducted with selective serotonin reuptake inhibitors have led to controversial results of effectiveness for TTM. Here, we report a female patient whose TTM symptoms increased after fluoxetine use...
January 23, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28118167/three-year-retention-rates-of-levetiracetam-topiramate-and-oxcarbazepine-a-retrospective-hospital-based-study
#5
Jun-Sang Sunwoo, Byeong-Su Park, Seon Jae Ahn, Sungeun Hwang, Chan-Young Park, Jin-Sun Jun, Dong Wook Kim, Soon-Tae Lee, Keun-Hwa Jung, Kyung-Il Park, Kon Chu, Ki-Young Jung, Sang Kun Lee
OBJECTIVES: We evaluated and compared the 3-year retention rates of levetiracetam (LEV), topiramate (TPM), and oxcarbazepine (OXC) in patients with epilepsy in routine clinical practice. METHODS: We retrospectively reviewed medical records of patients with epilepsy who were newly prescribed LEV, TPM, or OXC from 2006 to 2010. The retention rates were estimated by the Kaplan-Meier analysis, and independent risk factors for drug discontinuation were analyzed by the Cox regression method...
January 23, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28085707/citicoline-combination-therapy-for-major-depressive-disorder-a-randomized-double-blind-placebo-controlled-trial
#6
RANDOMIZED CONTROLLED TRIAL
Mahtab Roohi-Azizi, Somaye Arabzadeh, Meysam Amidfar, Samrand Salimi, Mohammad Reza Zarindast, Ali Talaei, Shahin Akhondzadeh
OBJECTIVE: Residual symptoms of major depressive disorder are a source of long-term morbidity. New therapeutic strategies are required to alleviate this morbidity and enhance patient quality of life. Citicoline has been used for vascular accidents and has been effective in cognitive rehabilitation. It has been used successfully to reduce craving in patients with substance abuse disorder and for mood management of bipolar disorder. Here, we test citicoline effectiveness as an adjuvant therapy in major depression...
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27941528/efficacy-of-the-treatments-used-in-multiple-sclerosis-from-meta-analysis-to-number-needed-to-treat
#7
Antonio J García-Ruiz, Guillermo Izquierdo-Ayuso, Guillermo Navarro-Mascarell, Ana C Montesinos-Gálvez, Francisco Martos-Crespo, Francisco Jódar-Sánchez, Manuel Correa, Nuria García-Agua Soler
: The aim of this study was to analyze the efficacy of drugs used in relapsing-remitting multiple sclerosis, first- and second-line drugs, using the number needed to treat (NNT) as a measure of efficacy. METHODS: Data from randomized clinical trials were analyzed for 3 categories of clinical efficacy outcomes: relapse, change in Expanded Disability Status Scale, and number of new lesions in magnetic resonance imaging. Meta-analysis results are expressed as odds ratios...
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27941527/striatal-dopamine-transporter-modulation-after-rotigotine-results-from-a-pilot-single-photon-emission-computed-tomography-study-in-a-group-of-early-stage-parkinson-disease-patients
#8
Carlo Rossi, Dario Genovesi, Paolo Marzullo, Assuero Giorgetti, Elena Filidei, Giovanni Umberto Corsini, Ubaldo Bonuccelli, Roberto Ceravolo
INTRODUCTION: Several in vitro data have reported negative interference by dopamine-agonists on the expression of dopamine transporter (DAT), whereas the majority of imaging studies have shown that neither L-dopa nor dopamine-agonists interfere with DAT availability. As yet, there are no in vivo studies on DAT expression after treatment with rotigotine. METHODS: We evaluated presynaptic nigrostriatal function in 8 patients with de novo Parkinson disease (age, 59 ± 6...
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27941526/epigallocatechin-gallate-extends-therapeutic-window-of-recombinant-tissue-plasminogen-activator-treatment-for-brain-ischemic-stroke-a-randomized-double-blind-and-placebo-controlled-trial
#9
RANDOMIZED CONTROLLED TRIAL
Xue-Hui Wang, Yi-Ping You
OBJECTIVES: Recombinant tissue plasminogen activator (rt-PA) is a safe and effective treatment for acute brain ischemia stroke, albeit with a narrow therapeutic window. We aimed to assess the effect of epigallocatechin gallate (EGCG) in extending the rt-PA treatment window in this clinical trial among stroke patients. METHODS: Patients were randomly assigned according to their onset-to-treatment time (OTT) and were then treated with rt-PA simultaneously with EGCG or placebo...
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27941525/alcohol-sensitive-generalized-dystonia
#10
Federico Micheli, Claudia Uribe-Roca, Michel Saenz-Farret
We report the case of a 29-year-old male patient with a generalized and progressive dystonia that led him unable to stand. Multiple antidystonic treatments were tried without benefit. Alcohol test was positive with a dramatic improvement. To the best of our knowledge, this is the first reported case of generalized dystonia without other clinical manifestations sensitive to alcohol.
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27879551/no-superiority-of-treatment-with-osmotic-controlled-release-oral-delivery-system-methylphenidate-over-short-medium-acting-methylphenidate-preparations-in-the-rate-and-timing-of-injuries-in-children-with-attention-deficit-hyperactivity-disorder
#11
Pavel Golubchik, Arad Kodesh, Abraham Weizman
OBJECTIVES: Methylphenidate (MPH) treatment in patients with attention-deficit/hyperactivity disorder (ADHD) is reported to reduce the risk for injuries. In the present study, the rate and timing of injuries were compared among the various MPH preparations (4 and 6-8 vs 12 hour-acting) in children with ADHD. METHODS: This real-world retrospective study covered the years 2011 to 2013. Participants included 2042 youngsters (aged 4-18 years, 13.01 ± 3.2 years; 71...
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27879550/successful-treatment-of-brachial-plexopathy-due-to-herpes-zoster-infection-with-intravenous-immunoglobulin
#12
Michel Sáenz-Farret, Valeria Sandoval-Rodríguez, Claudia Esther Paz-Navarro, Carlos Zúñiga-Ramírez
OBJECTIVE: The aim of this study was to report the case of a male patient with Parkinson disease who developed brachial plexopathy (BP) due to varicella-zoster virus, which was successfully treated with human immunoglobulin. METHOD: We report the case of a 75-year-old male subject with a diagnosis of Parkinson disease who came to our hospital complaining of pain, skin lesions, and strength loss in his right arm during the past 2 months. Physical examination revealed vesicular rash compatible with varicella-zoster virus lesions...
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27879549/fingolimod-use-for-the-treatment-of-multiple-sclerosis-in-a-clinical-practice-setting-in-madrid
#13
Victoria Galán Sánchez-Seco, Ignacio Casanova-Peño, Roberto Álvarez-Lafuente, Mónica Sánchez-Jiménez, Ángel García-Martínez, María Inmaculada Domínguez-Mozo, Ana María Arias-Leal, Marta García-Montojo, Rafael Arroyo-González
OBJECTIVE: To assess the effectiveness and safety of fingolimod use in a Spanish clinical practice setting. METHODS: Retrospective study with multiple sclerosis patients who received at least 1 fingolimod dose between January 2004 and January 2015. Effectiveness and safety data were collected during the entire treatment of each patient. Analysis was performed for the total population and stratified according to prior treatment, sex, and age at treatment initiation...
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27879548/switching-l-dopa-therapy-from-pulsatile-to-pulse-administration-reduces-motor-complications-in-parkinson-s-disease
#14
Giovanni Mostile, Alessandra Nicoletti, Valeria Dibilio, Antonina Luca, Loredana Raciti, Giorgia Sciacca, Calogero Edoardo Cicero, Rosario Vasta, Giulia Donzuso, Donatella Contrafatto, Mario Zappia
OBJECTIVE: To evaluate the severity of wearing-off and dyskinesia in patients with complicated Parkinson disease (PD) after switching L-dopa oral therapy from a "pulsatile" administration, consisting in intermittent multiple daily small doses of the drug, to a "pulse" administration, consisting in standard oral doses given at specific interdose intervals. METHODS: Thirty-four PD patients with motor complications were monitored twice with standardized waking day motor status evaluations using the Unified Parkinson Disease Rating Scale-Motor Examination (UPDRS-ME) and the Abnormal Involuntary Movement Scale (AIMS) after switching L-dopa administration modality from "pulsatile" to "pulse...
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27764051/quality-of-life-and-functioning-in-comorbid-posttraumatic-stress-disorder-and-major-depressive-disorder-after-treatment-with-citalopram-monotherapy
#15
Alexander J Steiner, Nathalie Boulos, James Mirocha, Stephanie M Wright, Katherine L Collison, Waguih W IsHak
OBJECTIVES: Posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) often have high comorbidity, consequently influencing patient-reported outcomes of depressive symptom severity, quality of life (QOL), and functioning. We hypothesized that the combined effects of concurrent PTSD and MDD would result in worse treatment outcomes, whereas individuals who achieved MDD remission would have better treatment outcomes. METHODS: We analyzed 2280 adult participants who received level 1 treatment (citalopram monotherapy) in the Sequenced Treatment Alternatives to Relieve Depression study, including 2158 participants with MDD without comorbid PTSD and 122 participants with MDD with comorbid PTSD (MDD + PTSD)...
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27755131/a-case-of-restless-legs-syndrome-related-to-opioid-discontinuation
#16
Grace H Lee, Alejandro V Jaen-Vinuales, Jonathan T Stewart
No abstract text is available yet for this article.
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27828814/recurrent-and-alternating-pisa-syndrome-a-surprising-entity
#17
Michel Sáenz-Farret, Alejandro Pellene, Federico Micheli
No abstract text is available yet for this article.
November 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27764053/escitalopram-associated-acute-urinary-retention-in-elderly-men-with-known-or-latent-benign-prostatic-hyperplasia-a-case-series
#18
Panagiotis Ferentinos, Dimitrios Margaritis, Athanasios Douzenis
Lower urinary tract outflow dysfunction is frequent in older men and a potential cause of serious complications such as acute urinary retention (AUR). Drug-induced AUR has only rarely been reported with selective serotonin reuptake inhibitors including escitalopram; reported cases had no history of urinary outflow dysfunction. We herein report the development of AUR after the introduction of escitalopram at a standard dose in 3 male patients with previously diagnosed or unknown/latent and nonsymptomatic benign prostatic hyperplasia...
November 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27764052/a-case-of-resistant-schizophrenia-successfully-treated-with-clozapine-long-acting-injectable-aripiprazole-combination
#19
Gianna Sepede, Giuseppe Di Iorio, Maria Chiara Spano, Marco Lorusso, Fabiola Sarchione, Rita Santacroce, Rosa Maria Salerno, Massimo Di Giannantonio
BACKGROUND: Treatment-resistant schizophrenia (TRS) is a condition characterized by intense symptom severity and poor response to different antipsychotic agents. The first therapeutic option in TRS is clozapine, but often high/medium doses are not tolerated. Adding an oral antipsychotic to low doses of clozapine is a promising strategy in the management of TRS. On the contrary, there are few data on combined clozapine/long-acting injectable (LAI) medications, and none on clozapine/LAI-aripiprazole...
November 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27764050/a-pilot-study-of-randomized-head-to-head-of-metformin-versus-topiramate-in-obese-people-with-schizophrenia
#20
RANDOMIZED CONTROLLED TRIAL
Po-Jui Peng, Pei-Shen Ho, Chia-Kuang Tsai, San-Yuan Huang, Chih-Sung Liang
OBJECTIVES: A number of research studies support the weight loss effects of metformin and topiramate for obese people with schizophrenia. However, only a few studies have addressed the sustainability of the body weight reduction after discontinuation of these drugs. Moreover, head-to-head studies are still lacking. The study aims to evaluate and compare the efficacy of metformin and topiramate in weight reduction and weight maintenance after discontinuation of these drugs in obese people with schizophrenia...
November 2016: Clinical Neuropharmacology
journal
journal
26752
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"